Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
NCT03177291Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pirfenidone in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase 1b Dose and Overall Response Rate. Started Sep 2017; status: completed.
02
Drugs
pirfenidone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03177291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177291.